论文部分内容阅读
记者从近日召开的中国医药产业发展高峰论坛上了解到,国家发改委正酝酿调整中成药价格的方案,预计明年年初出台。调整价格的对象是政府定价范围内非国家基本药物的中成药,而进入国家基本药物的中成药价格再另行研究。消息人士透露,在第1轮征求意见稿中,国家机密级及以上中药保密处方药品,国家发改委要求以现行零售价格为基础,统一按5个点降幅调整。在第2轮征求意见稿中又修改为“这类药品不降价”。这充分体现政府部门保护中药保密处方
Reporters learned from the recently held China Pharmaceutical Industry Summit Forum, the National Development and Reform Commission is planning to adjust the price of proprietary Chinese medicine program is expected early next year introduced. The object of price adjustment is the proprietary Chinese medicines of non-state essential medicines within the government pricing range, while the prices of proprietary Chinese medicines into the national essential medicines are studied separately. According to sources, in the first round of the draft for solicitation, the state secrets and above confidential prescription medicine, the National Development and Reform Commission requested the current retail price-based, unified by 5 points drop adjustment. In the second round of the draft was revised to “This kind of medicine does not cut ”. This fully reflects the government departments to protect the confidentiality of traditional Chinese medicine prescriptions